NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib

CompletedN/A

Sponsor: Pfizer

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Sunitinib

Countries: Canada

This is a retrospective, longitudinal cohort study that assessed clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib as first-line treatment.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosed with mRCC
* Initiated treatment post mRCC diagnosis and received sunitinib as first-line therapy
* Age 18 years or over at the time of mRCC diagnosis
* Actively treated at an IMDC clinical center

Exclusion Criteria:

* Initiated first line sunitinib treatment before 2010
* Had non-clear cell mRCC

Locations (1)

Calgary, Alberta, Canada